Difference between revisions of "Template:Main page"
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
<li>[[COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study]]</li> | <li>[[COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study]]</li> | ||
<li>[[Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis]]</li> | <li>[[Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis]]</li> | ||
| + | <li>[[Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea]]</li> | ||
| + | <li>[[COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study]]</li> | ||
| + | <li>[[A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19]]</li> | ||
| + | <li>[[Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection]]</li> | ||
| + | <li>[[Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine]]</li> | ||
</ul> | </ul> | ||
</div> | </div> | ||
| Line 24: | Line 29: | ||
category = Article | category = Article | ||
ordermethod = lastedit | ordermethod = lastedit | ||
| − | count = | + | count = 10 |
order = descending | order = descending | ||
</DynamicPageList> | </DynamicPageList> | ||
Revision as of 20:08, 22 July 2020
OMNIJOURNAL
Peer-review by everyone
COVID-19 Pandemic
- Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
- COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
- Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
- Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
- COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Recently Edited
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
- Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
- Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic
- Vitamin D deficiency causes a 10 times higher death rate in Covid-19 patients
- Early treatment with hydroxychloroquine: a country-randomized controlled trial
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- An Effective Treatment for Coronavirus (COVID-19)
- Americas Frontline Doctors Peer Review
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
- Gilead: Twenty-one billion reasons to discredit hydroxychloroquine peer review